

การตั้งตัวรับ ความคงตัวและชีวสมญูลของยาพ่นจมูกแซลมอนแคลซิโนิน

นางสาวบดีสุดา ชัยวงศ์ษา

ศูนย์วิทยทรัพยากร จุฬาลงกรณ์มหาวิทยาลัย

วิทยานิพนธ์นี้เป็นส่วนหนึ่งของการศึกษาตามหลักสูตรปริญญาเภสัชศาสตรมหาบัณฑิต

สาขาวิชาเภสัชกรรม ภาควิชาเภสัชกรรม

คณะเภสัชศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

ปีการศึกษา 2547

ISBN 974-53-2263-6

ลิขสิทธิ์ของจุฬาลงกรณ์มหาวิทยาลัย

FORMULATION, STABILITY AND BIOEQUIVALENCE OF
SALMON CALCITONIN NASAL SPRAYS


Miss Bordeesuda Suiwongsa

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย
A Thesis Submitted in Partial Fulfillment of the Requirements
for the Degree of Master of Science in Pharmacy


Department of Pharmacy
Faculty of Pharmaceutical Sciences
Chulalongkorn University
Academic Year 2004
ISBN 974-53-2263-6


Thesis Title Formulation, Stability and Bioequivalence of Salmon
Calcitonin Nasal Sprays
By Miss Bordeesuda Suiwongsa
Field of study Pharmacy
Thesis Advisor Associate Professor Parkpoom Tengamnuay, Ph.D.


Accepted by Faculty of Pharmaceutical Sciences, Chulalongkorn University in
Partial Fulfillment of the Requirements for the Master's Degree



Boonyong Tantisira Dean of Faculty of
Pharmaceutical Sciences
(Associate Professor Boonyong Tantisira, Ph.D.)


Thesis Committee


Porntip Nimmanitya Chairman
(Associate Professor Porntip Nimmanitya, M.Sc. in Pharm.)


Parkpoom Tengamnuay Thesis Advisor
(Associate Professor Parkpoom Tengamnuay, Ph.D.)


Uthai Suwanakoot Member
(Associate Professor Uthai Suwanakoot, Ph.D.)


Panida Vayumhasuwan Member
(Assistant Professor Panida Vayumhasuwan, Ph.D.)


Chatupon Chatigavanich Member
(Assistant Professor Chatupon Chatigavanich, M.D.)

นางสาวบดีสุดา ชัยวงศ์ษา: การตั้งตำรับ ความคงตัวและชีวสมมูลของยาพ่นจมูกแซลมอน
แคลซิโโนน (FORMULATION STABILITY AND BIOEQUIVALENCE OF SALMON
CALCITONIN NASAL SPRAYS) อ.ที่ปรึกษา: รศ.ดร.ภาคภูมิ เต็งอำนวย, จำนวน 169 หน้า
ISBN 974-53-2263-6

แคลซิโโนน(แซลมอน) เป็นเปปไทด์ที่ใช้ในการรักษาภาวะกระดูกพรุน และโรคความผิดปกติอื่นของกระดูก ในปัจจุบันยาที่มีใช้ในประเทศไทยอยู่ในรูปแบบยาฉีดและยาพ่นจมูก ซึ่งทั้งสองรูปแบบยังต้องนำเข้าจากต่างประเทศส่งผลให้ยา มีราคาแพงและมีการใช้ในวงจำกัด วัตถุประสงค์หลักของการศึกษาครั้งนี้คือต้องการที่จะพัฒนาตำรับยาแซลมอนแคลซิโโนนในรูปแบบยาพ่นจมูกที่มีความคงตัวดี มีชีวประสิทธิผลและมีราคาถูกลงกว่าเดิม ยาพ่นจมูกแซลมอนแคลซิโโนนถูกเตรียมขึ้นเป็นสองความแรงได้แก่ 100 และ 200 ยูนิต ตำรับละสองรุ่นการผลิต ยาพ่นจมูกที่เตรียมได้อยู่ในรูปสารละลายใส มีความเป็นกรดค่อนข้างและโนนิชิตที่เหมาะสม บรรจุใส่ขวดพ่นเฉพาะสามารถให้ลักษณะแต่ละครั้งพ่นเท่ากับ 0.09 มล. ทำการศึกษาความคงตัวในสภาพเก็บปกติ (4 องศาเซลเซียส) เป็นเวลา 12 เดือนและสภาพเร่งอุณหภูมิ (30 องศาเซลเซียส) เป็นเวลา 4 เดือน โดยเก็บตัวอย่างมาตรฐานตามช่วงเวลาที่กำหนดไว้ เพื่อหาปริมาณตัวยาสำคัญ และนอกเหนือไปจากนั้นได้ทำการหาปริมาณสารสำคัญ (แคลซิโโนน ชี) พร้อมกับปริมาณของเปปไทด์ที่มีโครงสร้างใกล้กัน (เอน-อะเซติดิ-ซิส-แคลซิโโนน) โดยใช้อัลฟ์แอลซี พนวจปริมาณตัวยาสำคัญของยาพ่นจมูกทุกรุ่นที่ผลิตยังคงอยู่ในช่วงร้อยละ 90 -115 ตลอดช่วงการเก็บตัวอย่าง การทดสอบอื่นได้แก่ ความใส ของโนไมลาลิตี ความสม่ำเสมอของการให้สเปรย์ และความเป็นกรดค่อนข้างของยาพ่นจมูก ตลอดระยะเวลาที่เก็บตัวอย่างพบว่าไม่มีการเปลี่ยนแปลงไปจากค่าเริ่มต้น เพื่อยืนยันในประสิทธิภาพของเครื่องพ่นได้ทำการทดสอบเพิ่มเรื่องการร้าวไหล การกระจายของขนาดละเอียดสเปรย์และรูปแบบของละเอียดสเปรย์ การศึกษาชีวประสิทธิผลของยาพ่นจมูกขนาดความแรง 200 ยูนิตที่เตรียมขึ้นกับยาต้นแบบ กระทำในอาสาสมัครชายสุขภาพดี จำนวน 12 คน โดยใช้แบบแผนการทดลองข้ามสลับชนิด สองทาง อาสาสมัครได้รับยาจำนวน 400 ยูนิต (200 ยูนิตพ่นสองครั้ง) เก็บตัวอย่างพลาสมาและทำการวิเคราะห์โดยใช้เทคนิคทางเคมีอิมมิวนโโลยี จากการวิเคราะห์ข้อมูลทางสถิติพบว่า ค่าความเข้มข้นของระดับยาสูงสุดในพลาสma และพื้นที่ใต้เส้นโค้งระหว่างความเข้มข้นของยาในพลาสماกับเวลาของผลิตภัณฑ์ทั้งสองตัวอย่าง ไม่มีความแตกต่างอย่างมีนัยสำคัญ ($p>0.05$) ค่าร้อยละ 90 ของช่วงความเชื่อมั่นของสัดส่วนของแต่ละพารามิเตอร์ทางเภสัชศาสตร์เทียบกับยาต้นแบบอยู่ภายในช่วงร้อยละ 80 -125 ดังนั้นสามารถสรุปได้วายาพ่นจมูกที่เตรียมขึ้นมีชีวสมมูลกับผลิตภัณฑ์ต้นแบบและมีความเท่าเทียมกันในทางเภสัชกรรม


ภาควิชา

เภสัชกรรม

ลายมือชื่อนิสิต.....บดีสุดา ชัยวงศ์ษา

สาขาวิชา

เภสัชกรรม

ลายมือชื่ออาจารย์ที่ปรึกษา.....

ปีการศึกษา

2547

4476581333: MAJOR PHARMACY

KEY WORD: FORMULATION / BIOEQUIVALENCE / SALMON CALCITONIN /
NASAL SPRAY

BORDEESUDA SUIWONGSA: FORMULATION, STABILITY AND
BIOEQUIVALENCE OF SALMON CALCITONIN NASAL SPRAYS.

THESIS ADVISOR: ASSOC. PROF. PARKPOOM TENGAMNUAY, Ph. D.
169 pp. ISBN 974-53-2263-6

Salmon calcitonin (CT) is a peptide used in the treatment of osteoporosis and other bone-related disorders. It is currently available in Thailand as an injection and a nasal spray solution, both of which are imported resulting in a high cost of medication and limited usage. The main objective of this study was to develop salmon CT nasal spray preparations that could provide acceptable stability and bioavailability at a more economical cost. Two strengths (100 and 200 IU per actuation) of salmon CT nasal sprays were prepared (two batches each). The formulation was an isotonic solution of synthetic salmon CT with appropriate preservative, buffer and tonicity adjuster. A special spray pump was used that could provide an accurate and reproducible spray volume of 0.09 ml per actuation. The stability studies consisted of real-time testing at 4 °C (recommended storage condition) for 12 months and at 30 °C (accelerated condition) for 4 months. Samples were taken periodically to determine for salmon CT content as well as its degradation product (calcitonin C) and related peptide (N-acetyl-cys¹-calcitonin) by HPLC. The percent labeled amount of all four batches was within 90.0 – 115.0 % ranges. The prepared nasal sprays also complied with the tests for calcitonin C and related peptide as well as the clarity, pH, osmolarity, uniformity of mass and sterility tests under both storage conditions. The reproducibility of the pump spray performance was also confirmed based on the results from the leak test, droplet size distribution and spray pattern evaluation. The *in vivo* bioavailability of the test product (200 IU strength) relative to the innovator product was further evaluated in 12 healthy male volunteers. Each subject received a total single dose of 400 IU salmon CT in a two-way crossover study. The plasma concentrations of salmon CT were determined by radioimmunoassay. There were no statistically significant differences in the corresponding pharmacokinetic parameters (AUC and C_{max}) between the two products ($p > 0.05$, ANOVA). The 90% confidence intervals for the ratio of the two parameters (test to innovator) based on the log-transformed data were within the 80.0 – 125.0% bioequivalence range. Thus, it can be concluded that the prepared salmon CT nasal spray solutions were both pharmaceutically equivalent and bioequivalent to the innovator product.

Department	Pharmacy	Student's signature.....
Field of study	Pharmacy	Advisor's signature.....
Academic year	2004	

ACKNOWLEDGEMENTS

First of all, I would like to express my profound gratitude to my advisor, Associate Professor Parkpoom Tengamnuay, for his valuable advises, kindness and encouragement through out the period of my study.

I wish to express appreciation to all members of my thesis committee for their valuable discussion.

I would like to sincerely thanks to all staff of Pharmacy Department, Faculty of Pharmaceutical Sciences and the scientists of the Pharmaceutical Technology Service center, Chulalongkorn University for providing facilities and valuable suggestions during my study.

Special thanks given to Pharmacy Department, Siriraj Hospital for permission of my education.

Thank you for Greater Pharma Ltd. Part, for financial support of the project.

I am grateful for the expert technical assistance of the Office of Atoms for Peace for kind provision of RIA determination facilities.

Finally, I am most grateful to my parents and all friends for their love and encouragement.

ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

CONTENTS

	Page
Thai Abstract.....	iv
English Abstract.....	v
Acknowledgements.....	vi
Contents.....	vii
List of Tables.....	xi
List of Figures.....	xvi
List of Abbreviations.....	xviii
CHAPTER	
I INTRODUCTION.....	1
II LITERATURES REVIEW.....	5
1. Nasal Route of Drug Delivery.....	5
1.1 Anatomy of the Nose.....	6
1.2 Nasal Passage.....	7
1.3 Nasal Epithelium.....	9
1.4 Nasal Drugs Absorption.	11
1.5 The Site of Drug Deposition in the Nasal Cavity.....	12
1.6 Factors Affecting Absorption of Drugs from the Nasal Mucosa..	13
1.6.1 Physiological Factors.....	14
1.6.2 Nasal Formulations.....	16
1.6.2.1 Physiological Properties of the Drug.....	16
1.6.2.2 Physiological Properties of the Formulation....	18
1.6.3 Dosage Form and Device Related Factor.....	18
2. Calcitonin.....	20
2.1 Biochemistry of Calcitonin.....	20
2.2 Biosynthesis of Calcitonin.....	21
2.3 Regulation of Secretion.....	22
2.4 Metabolism and Excretion.	23
2.5 Mechanism of Action.....	23
2.6 Physiological Effects of Calcitonin.....	24
2.7 Therapeutic Uses of Calcitonin.....	24
2.8 Permeation of CT Across Nasal Mucosa	26

CHAPTER	Page
2.9 Side Effect of Salmon CT.....	26
2.10 Physicochemical Characteristics of Salmon CT	27
2.11 Degradation Mechanisms.....	27
3. Possibility and Benefits of Local Manufacture of Salmon CT.....	29
4. Assessment of Salmon CT Absorption after Nasal Administration....	30
4.1 Radioimmunoassay.....	30
4.2 Principles of Radioimmunoassay.....	30
III MATERIALS AND METHODS.....	33
1. Assay of Salmon CT Powder (Standardization)	36
1.1 Preparation of Standard Reference Solution.....	36
1.2 Preparation of Test Solution.....	36
1.3 Preparation of Mobile Phases.....	36
1.4 High Performance Liquid Chromatographic (HPLC) Conditions	36
2. Assay of Water and Acetic Acid Contents.....	39
3. Preparation of Salmon CT Nasal Solutions.....	40
4. Stability Test.....	46
5. Content of Salmon CT in the Nasal Sprays.....	46
5.1 Preparation of Test Solution	46
5.2 Preparation of Working Standard.....	47
5.3 Preparation of Mobile Phases.....	47
5.4 HPLC Conditions.....	47
5.5 Standard Calibration Curve.....	48
5.6 Assay Validation.....	49
5.6.1 Accuracy.....	49
5.6.2 Precision.....	49
6. Related Peptide in the Nasal Sprays.....	50
7. Calcitonin C.....	51
8. Acidity.....	51
9. Osmolarity.....	52
10. Clarity.....	52
11. Sterility Test.....	52
12. Uniformity of Mass.....	52

CHAPTER	Page
13. Droplet Size Measurement.....	53
14. Spray Pattern.....	53
15. Leak Test.....	54
16. In Vivo Study.....	55
16.1 Products.....	55
16.2 Subjects.....	55
16.3 Inclusion Criteria.....	55
16.4 Exclusion Criteria.....	55
16.5 Dose and Drug Administration.....	56
16.6 Subject Monitoring.....	56
16.7 Experimental Design.....	56
16.8 Sample Collection.....	57
16.9 Analysis of Salmon CT in Plasma.....	57
16.10 Data Analysis.....	59
17. Evaluation of Bioequivalence.....	60
17.1 Statistical Test.....	60
17.2 Construction of 90% Confidence Interval.....	60
IV RESULTS AND DISCUSSION.....	61
1. Assay of Salmon CT Powder (Standardization of Raw Materials).....	61
2. Assay Validation of Salmon CT.....	64
2.1 Standard Calibration Curves.....	64
2.2 Accuracy.....	66
2.3 Precision.....	66
3. Assay of Percent Labeled Amount of Salmon CT in the Nasal Sprays.	70
4. Stability of Salmon CT Nasal sprays.....	70
4.1 Percent Labeled Amount.....	70
4.2 Calcitonin C.....	74
4.3 Related Peptide.....	77
4.4 Acidity.....	80
4.5 Osmolarity.....	81
4.6 Clarity.....	82
4.7 The Sterility Test.....	83
4.8 Uniformity of Mass (Weight per spray).....	84

CHAPTER	Page
5. Leak Test.....	85
6. Droplet Size Measurement and Droplet Size Distribution.....	85
7. Spray Pattern Test.....	88
8. In vivo Study.....	91
8.1 Analysis of Calcitonin in Plasma.....	91
8.2 Determination of Bioavailability Parameters (AUC, Cmax and Tmax).....	95
8.3 Bioequivalence Evaluation.....	108
V CONLUSIONS.....	128
REFERENCES.....	131
APPENDICES.....	138
VITA.....	169



ศูนย์วิทยทรรพยากร
จุฬาลงกรณ์มหาวิทยาลัย

LIST OF TABLES

Table	page
1 Possibilities for nasal delivery of drugs.....	5
2 Variable factors affecting the absorption of drugs through the nasal mucosa.....	13
3 Degradation mechanisms for peptides and proteins in general and their relevance for calcitonin (Cholewinski, Luckel and Horns, 1996).....	29
4 The gradient elution program operated for salmon CT.....	37
5 Formulas of salmon CT nasal solutions (100 and 200 IU per spray).....	42
6 Tests and specifications for finished product of salmon CT nasal sprays (Both 100 and 200 IU per spray). Each test was performed in duplicate for all batches.....	43
7 Stability testing schedule of real-time and accelerated studies.....	46
8 The gradient elution program operated for salmon CT in nasal solution...	48
9 The gradient elution program operated for related peptide.....	50
10 Sequences of drug administration by Latin square design.....	57
11 Concentration of Ultra-sensitive salmon CT standards.....	59
12 Content of salmon CT expressed as % net peptide and % assay (purity)...	62
13 Peak areas of salmon CT standard solutions for the construction of calibration curve in Figure 14.....	65
14 Accuracy data for the HPLC determination of salmon CT	67
15 Within-run precision data for HPLC determination of salmon CT.....	68
16 Between-run precision data for HPLC determination of salmon CT	68
17 Repeatability of HPLC injection.....	69
18 Percent labeled amount of salmon CT at different storage condition times.....	71
19 The extent of calcitonin C in the salmon CT nasal sprays upon storage at different temperatures	76
20 Relative retention time of N-acetyl-cys-1 calcitonin EPCRS and the percent related peptide found in the salmon CT nasal sprays.....	78
21 pH of the nasal spray preparations stored at 30 and 4 °C	80
22 Osmolarity of the nasal spray preparations stored at 30 °C and 4 °C.....	81

Table	Page
23 Clarity of the nasal spray preparations after storage at 30 °C	82
24 Clarity of the nasal spray preparations after storage at 4 °C	82
25 Sterility test results after storage at 4 and 30 °C	83
26 Uniformity of mass (averaged weight per spray of ten bottles) determined at different storage times and temperatures.....	84
27 Leak Test results.....	85
28 Droplet size measurement of salmon CT nasal spray 100 IU and 200 IU (placebo A and B)	86
29 Average diameters at different spray angles of salmon CT nasal spray 100 IU and 200 IU (placebo A and B).....	90
30 Test products.....	91
31 Comparison of the initial percent labeled amount and other <i>in vitro</i> quality parameters between the innovator and the test nasal spray products (strength 200 IU per spray).....	92
32 Plasma Salmon CT Interpolated Concentrations (pg/ml) of 12 Subjects Following Intranasal Administration of The Test Preparation (200 IU per actuation) at 400 IU dose.....	97
33 Plasma Salmon CT Interpolated Concentrations (pg/ml) of 12 Subjects Following Intranasal Administration of The Test Preparation (Miacalcic® 200 IU per actuation) at 400 IU dose.....	98
34 Plasma Salmon CT Concentration (pg/ml) of 12 subjects following Intranasal Administration of the test preparation (200 IU per actuation) at 400 IU dose.....	99
35 Plasma Salmon CT Concentration (pg/ml) of 12 subjects following Intranasal Administration of the innovator product (Miacalcic® 200 IU per actuation) at 400 IU dose	100
36 Area under the plasma salmon CT concentration - time curve from time 0 to the last detectable time point (AUC _{0-t}), following intranasal administration of 400 IU salmon CT nasal spray to 12 subjects	114
37 Area under the plasma salmon CT concentration - time curve from time 0 to infinite time (AUC _{0-∞}), following intranasal administration of 400 IU salmon CT nasal spray to 12 subjects.....	115

Table		Page
38	Analysis of variance for two-way crossover study at $\alpha = 0.05$ of ln AUC _{0-t} following intranasal administration of 400 IU salmon CT nasal spray to 12 subjects	116
39	Analysis of variance for two-way crossover study at $\alpha = 0.05$ of ln AUC _{0-∞} following intranasal administration of 400 IU salmon CT nasal spray to 12 subjects.....	117
40	The exact 90 % confidence interval for the ratio of the area under the plasma concentration – time curve (AUC _{test} /AUC _{innovator}) following intranasal administration of 400 IU salmon CT nasal spray (test and innovator products).....	118
41	Peak plasma salmon CT concentration (Cmax) following intranasal administration of 400 IU nasal spray (test and innovator products)to 12 subjects.....	119
42	Analysis of variance for two-way crossover study at $\alpha = 0.05$ of ln Cmax following intranasal administration of 400 IU salmon CT nasal spray to 12 subjects.....	120
43	The exact 90 % confidence interval for the ratio of peak plasma concentration (Cmax _{test} /Cmax _{innovator}) following intranasal administration of 400 IU salmon CT nasal spray (test and innovator products).....	121
44	Time to maximum concentration (T _{max}) of salmon CT following intranasal administration of 400 IU nasal spray (test and innovator products).....	122
45	Elimination half-life (t _{1/2}) of salmon CT following intranasal administration of 400 IU nasal spray (test and innovator products).....	123
46	Analysis of variance for two-way crossover study at $\alpha = 0.05$ of elimination half life (t _{1/2}) following intranasal administration of 400 IU salmon CT nasal spray to 12 subjects.....	124
47	Elimination rate constant (K _e) of salmon CT following intranasal administration of 400 IU nasal spray (test and innovator products).....	125

Table		Page
48	Analysis of variance for two-way crossover study at $\alpha = 0.05$ of elimination constant (K_e) following intranasal administration of 400 IU salmon CT nasal spray to 12 subjects.....	126
49	Principle Pharmacokinetic Parameters of Salmon CT following intranasal administration of 400 IU nasal spray (test and innovator products).....	127
50	Individual Peak Area of analysis for salmon CT <i>EPCRS</i>	140
51	Peak Area for Five Determination of Salmon CT (Bachem AG, Bubendorf, Switzerland) Lot-No. 0557992.....	141
52	Individual Peak areas of salmon CT standard solutions for construction calibration curve.....	144
53	Individual peak areas of salmon CT standard solutions for accuracy data.	145
54	Individual peak areas of salmon CT standard solutions for within-run precision data.....	146
55	Individual peak areas of salmon CT standard solutions for between-run precision data.....	146
56	Demographic Data of Subjects Participated in This Study.....	152
57	Blood Chemical tests of subjects Participated in This Study.....	153
58	Typical RIA Standard Curve for Determination of Plasma Salmon CT....	154
59	Determination of reference standard salmon CT Level I,II and III.....	154
60	Logarithmically transformed of pharmacokinetic parameters (AUC _{0-t} , AUC _{0-∞} and C _{max}) of 12 subjects following intranasal administration of the Test's product.....	154
61	Logarithmically transformed of pharmacokinetic parameters (AUC _{0-t} , AUC _{0-∞} and C _{max}) of 12 subjects following intranasal administration of the Innovator's product.....	155
62	Peak area of CT and N-acetyl-cys ¹ -calcitonin for assay percent of related peptide.....	161
63	Peak area of CT and Calcitonin C for determination percent of Calcitonin C.....	162
64	Test Microorganisms suitable for use in growth promotion test and the validation tests for the Bacteriostatic and fungistasis.....	163

Table		Page
65	Minimum number of articles to be tested in relation to the number of article in the batch.....	164
66	Quantities of articles for liquid products.....	164
67	Individual Data of Droplet Size Distribution (placebo A).....	165
68	Individual Data of Droplet Size Distribution (placebo B).....	166
69	Individual Data for Determination Spray Pattern Analysis (Placebo A)...	167
70	Individual Data for Determination Spray Pattern Analysis (Placebo B)...	168



ศูนย์วิทยทรัพยากร
จุฬาลงกรณ์มหาวิทยาลัย

LIST OF FIGURES

Figure		page
1	Diagram showing the lateral wall of the nasal cavity.....	7
2	The upper air way seen from the midline (A) and section through the main nasal passage showing the nasal septum, folds of turbinates, and airway (B).....	8
3	Schematic diagram of olfactory epithelium.....	9
4	Microscopic diagram of the major cell types in the nasal airway epithelium	11
5	Amino acid sequence of salmon calcitonin.....	20
6	Comparison of primary structures of salmon and other calcitonins.....	21
7	Structure of the calcitonin gene.....	22
8	Mechanism of the cellular action of calcitonin.....	23
9	Diagram shown method of Radioimmunoassay.....	31
10	Parts of nasal spray bottle (Ing. Erich Pfeiffer GmbH, Radolfzell, Germany).....	44
11	Crimping machine (Mary Commercial Thailand)	45
12	Image analysis of spray pattern and spray angle.....	54
13	HPLC chromatogram of salmon CT.(A) Blank; (B) Reference solution; and (C) Test solution.....	63
14	Representative calibration curve of salmon CT at different concentrations.....	64
15	Diagram showing linearity of method ($R = 0.999$).....	67
16	Percent labeled amount of salmon CT nasal sprays during storage at accelerated condition (30°C).....	72
17	Percent labeled amount of salmon CT nasal sprays during storage at recommended condition (4° C).....	73
18	HPLC chromatograms of calcitonin C reference solution.(A) Blank; (B) Calcitonin C reference solution.....	75
19	Chromatograms showing related peptide and salmon CT peaks.....	79
20	Representative particle size distribution of calcitonin nasal spray (Placebo B).....	87

Figure		page
21	Typical shape of spray pattern at spray angle 68°, 76° and 73°.....	89
22	Representative standard RIA curve for Salmon CT	92
23	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.1 after intranasal administration of 400 IU salmon CT.....	101
24	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.2 after intranasal administration of 400 IU salmon CT.....	101
25	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.3 after intranasal administration of 400 IU salmon CT.....	102
26	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.4 after intranasal administration of 400 IU salmon CT.....	102
27	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.5 after intranasal administration of 400 IU salmon CT.....	103
28	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.6 after intranasal administration of 400 IU salmon CT.....	103
29	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.7 after intranasal administration of 400 IU salmon CT.....	104
30	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.8 after intranasal administration of 400 IU salmon CT.....	104
31	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.9 after intranasal administration of 400 IU salmon CT.....	105
32	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.10 after intranasal administration of 400 IU salmon CT.....	105
33	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.11 after intranasal administration of 400 IU salmon CT.....	106
34	Plasma salmon CT concentration (pg/ml) versus time (min) of subject No.12 after intranasal administration of 400 IU salmon CT.....	106
35	Mean Plasma salmon CT concentration (pg/ml) versus time (min) after intranasal administration of 400 IU salmon CT to healthy subjects.....	107

LIST OF ABBREVIATIONS

%	=	Percent
% L.A.	=	percent labeled amount
°C	=	degree Celsius
µg	=	Microgram
µL	=	Microliter
µm	=	Micrometer
¹²⁵ I	=	Iodine 125
A°	=	Angstrom
ANOVA	=	analysis of variance
AUC	=	area under the plasma concentration – time
B	=	bound radio-labeled antigen
B ₀	=	unbound radio-labeled antigen
BMI	=	body mass index
BP	=	British Pharmacopoeia
CDER	=	Center for Drug Evaluation and Research
C.I.	=	confidence interval
C.V.	=	coefficient of variation
cm	=	Centimeter
C _{max}	=	peak plasma concentration
CPM	=	Counts per minute
CT	=	Calcitonin
D ₁₀	=	10% of the droplet diameters are smaller than the indicated value
D ₅₀	=	50% of the droplet diameters are smaller than the indicated value
D ₉₀	=	90% of the droplet diameters are smaller than the indicated value
Da	=	Dalton
EDQM	=	European Directorate for the Quality Medicine
EP	=	European Pharmacopoeia
EPCRS	=	European Pharmacopoeia Control Reference

FDA	=	Food and drug administration
HPLC	=	high performance liquid chromatography
hr	=	Hour
I.U.	=	international unit
k_e	=	elimination rate constant
kg	=	Kilogram
L	=	Liter
LLOQ	=	lower limit of quantitation
Ln	=	natural logarithms
m	=	Meter
M	=	Molar
Mfg.	=	Manufacturing
m^2	=	square meter
mg	=	Milligram
min	=	Minute
mL	=	Milliliter
mm	=	Milliliter
mOsmol	=	Milliosmol
MSE	=	mean square error
MW	=	molecular weight
N	=	Normality
nm	=	Nanometer
No.	=	Number
NSB	=	non - specific binding
pg	=	Pictogram
q.s.	=	quantum sufficiat
r^2	=	coefficient of determination
RIA	=	Radioimmunoassay
rpm	=	revolution per minute
S.D.	=	standard deviation
S.E.	=	standard error
t _{1/2}	=	half life
t _{max}	=	time to peak plasma concentration

USP	=	United States Pharmacopoeia
UV	=	Ultraviolet
v/v	=	volume by volume
w/v	=	weight by volume
w/w	=	weight by weight
WHO	=	World Health Organization

